PE20030472A1 - SOLID FORMULATION TO USE AS A DRUG BASED ON A PIPERAZINUREA DERIVATIVE - Google Patents

SOLID FORMULATION TO USE AS A DRUG BASED ON A PIPERAZINUREA DERIVATIVE

Info

Publication number
PE20030472A1
PE20030472A1 PE2002001027A PE2002001027A PE20030472A1 PE 20030472 A1 PE20030472 A1 PE 20030472A1 PE 2002001027 A PE2002001027 A PE 2002001027A PE 2002001027 A PE2002001027 A PE 2002001027A PE 20030472 A1 PE20030472 A1 PE 20030472A1
Authority
PE
Peru
Prior art keywords
polyuble
cellulose
methyl
refers
solid formulation
Prior art date
Application number
PE2002001027A
Other languages
Spanish (es)
Inventor
Ralph Lipp
Heiko Kranz
Christoph Volkel
Herbert Wiesinger
Johannes Tack
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of PE20030472A1 publication Critical patent/PE20030472A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE REFIERE A UNA FORMULACION SOLIDA QUE CONTIENE a)(2R)-1-((4-CLORO-2-(UREIDO)FENOXI)METIL)CARBONIL-2-METIL-4-(4-FLUORO-BENCIL)-PIPERAZINA (ANTAGONISTA DEL RECEPTOR CCR-1), b)MATRIZ POLIMERICA, SE SELECCIONA DE DERIVADOS DE CELULOSA, ACRILICOS, POLIMEROS VINILICOS, POLIANHIDROS, POLIESTER POLIORTOESTER, POLIURETANOS, POLICARBONATOS, ENTRE OTROS O UNA MEZCLA DE POLIVINIL-PIRROLIDONA SOLUBLE EN AGUA Y POLIVINILACETATO INSOLUBLE EN AGUA, c)ACIDO ORGANICO COMO FUMARICO, CITRICO, ASCORBICO, MALEICO, TARTARICO, SUCCINICO, GLUTARICO, SORBICO, ENTRE OTROS, d)LUBRICANTE, e)EXCIPIENTE TAL COMO LACTOSA, DIFOSFATO DE CALCIO, ALMIDON, CELULOSA CRISTALINA; CARACTERIZADA PORQUE EL 90% DEL TAMANO DE PARTICULAS DE LAS MEZCLAS EN POLVO SE UBICAN EN EL RANGO DE 0,1 A 750µm. TAMBIEN SE REFIERE A PROCEDIMIENTOS PARA LA PREPARACION. LA FORMULACION DE LA COMPOSICION AUMENTA LA SOLUBILIDAD Y LIBERACION DEL COMPUESTO INDEPENDIENTEMENTE DEL pH Y PUEDE SER UTIL PARA EL TRATAMIENTO DE ENFERMEDADES INFLAMATORIAS, ESCLEROSIS MULTIPLE, ARTRITIS REUMATOIDE, PSORIASIS, DERMATITIS ATOPICAREFERS TO A SOLID FORMULATION CONTAINING a) (2R) -1 - ((4-CHLORINE-2- (UREIDE) PHENOXY) METHYL) CARBONYL-2-METHYL-4- (4-FLUORO-BENZYL) -PIPERAZINE (ANTAGONIST OF THE RECEIVER CCR-1), b) POLYMERIC MATRIX, SELECTED FROM DERIVATIVES OF CELLULOSE, ACRYLICS, VINYL POLYMERS, POLYANHYDRES, POLYORTOESTER POLYESTER, POLYURETHANES, POLYCARBONATES, BETWEEN OTHER WATER-INSIVINY-WATER-POLYUBLE-POLYUBLE-POLYLUBLE MIXTURE , c) ORGANIC ACID SUCH AS FUMARIC, CITRIC, ASCORBIC, MALEIC, TARTARIC, SUCCINIC, GLUTARIC, SORBIC, AMONG OTHERS, d) LUBRICANT, e) EXCIPIENT SUCH AS LACTOSE, CALCIUM DIPHOSPHATE, STARCH, CELLULOSE; CHARACTERIZED BECAUSE 90% OF THE PARTICLE SIZE OF POWDER MIXTURES ARE LOCATED IN THE RANGE OF 0.1 TO 750µm. IT ALSO REFERS TO PROCEDURES FOR PREPARATION. THE FORMULATION OF THE COMPOSITION INCREASES THE SOLUBILITY AND RELEASE OF THE COMPOUND INDEPENDENTLY OF THE pH AND MAY BE USEFUL FOR THE TREATMENT OF INFLAMMATORY DISEASES, MULTIPLE SCLEROSIS, RHEUMATOID ARTHRITIS, PSORIASIS, ATOPIC DERMATITIS

PE2002001027A 2001-10-18 2002-10-17 SOLID FORMULATION TO USE AS A DRUG BASED ON A PIPERAZINUREA DERIVATIVE PE20030472A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10152351A DE10152351B4 (en) 2001-10-18 2001-10-18 Solid drug formulation for a piperazine urea derivative

Publications (1)

Publication Number Publication Date
PE20030472A1 true PE20030472A1 (en) 2003-06-16

Family

ID=7703496

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002001027A PE20030472A1 (en) 2001-10-18 2002-10-17 SOLID FORMULATION TO USE AS A DRUG BASED ON A PIPERAZINUREA DERIVATIVE

Country Status (23)

Country Link
EP (1) EP1435917A1 (en)
JP (1) JP2005506365A (en)
KR (1) KR20040047920A (en)
CN (1) CN1571660A (en)
AR (1) AR037111A1 (en)
AU (1) AU2002333896B2 (en)
BR (1) BR0213340A (en)
CA (1) CA2463951A1 (en)
CO (1) CO5580740A2 (en)
DE (1) DE10152351B4 (en)
EC (1) ECSP045108A (en)
HR (1) HRP20040435A2 (en)
IL (1) IL161166A0 (en)
MX (1) MXPA04003522A (en)
NO (1) NO20042022L (en)
NZ (1) NZ532287A (en)
PE (1) PE20030472A1 (en)
PL (1) PL367987A1 (en)
RS (1) RS32204A (en)
RU (1) RU2311172C2 (en)
UY (1) UY27500A1 (en)
WO (1) WO2003035037A1 (en)
ZA (1) ZA200403781B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60222667T2 (en) 2001-06-27 2008-07-17 Smithkline Beecham Corp. FLUORPYRROLIDINES AS DIPEPTIDYLPEPTIDASE INHIBITORS
EP1749519A1 (en) 2005-08-05 2007-02-07 Schering Aktiengesellschaft Dosage form with pH-independent sustained release for active substances with pH-dependent solubility
US20090169617A1 (en) * 2006-04-26 2009-07-02 Panagiotis Keramidas Controlled Release Formulations Comprising Uncoated Discrete Unit(s) and an Extended Release Matrix
DE102008047910A1 (en) 2008-09-19 2010-03-25 Molkerei Meggle Wasserburg Gmbh & Co. Kg Tabletting excipient based on lactose and cellulose
KR101654582B1 (en) 2016-05-12 2016-09-06 그린로드(주) Conical Shaped Buoyant Polymer Filter and Apparatus for Manufacturing the same and Method for Manufacturing the same and Water Treatment Filter including the same
RU2729223C1 (en) * 2020-05-13 2020-08-05 Мераб Георгиевич Чикобава Dosage form for amplification of nucleic acids

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207665B1 (en) * 1997-06-12 2001-03-27 Schering Aktiengesellschaft Piperazine derivatives and their use as anti-inflammatory agents
ATE337307T1 (en) * 1998-02-05 2006-09-15 Pfizer Prod Inc NEW DIHYDROXYHEXANIC ACID DERIVATIVES
ATE400251T1 (en) * 1999-02-09 2008-07-15 Pfizer Prod Inc COMPOSITIONS OF BASIC DRUGS WITH IMPROVED BIOAVAILABILITY

Also Published As

Publication number Publication date
AU2002333896A2 (en) 2003-05-06
DE10152351A1 (en) 2003-05-08
IL161166A0 (en) 2004-08-31
RU2004115328A (en) 2005-06-10
UY27500A1 (en) 2003-06-30
RS32204A (en) 2006-10-27
AU2002333896B2 (en) 2007-07-26
EP1435917A1 (en) 2004-07-14
KR20040047920A (en) 2004-06-05
HRP20040435A2 (en) 2005-06-30
PL367987A1 (en) 2005-03-21
NZ532287A (en) 2007-04-27
DE10152351B4 (en) 2005-09-22
MXPA04003522A (en) 2004-07-23
ECSP045108A (en) 2004-06-28
CO5580740A2 (en) 2005-11-30
CA2463951A1 (en) 2003-05-01
JP2005506365A (en) 2005-03-03
NO20042022L (en) 2004-05-14
WO2003035037A1 (en) 2003-05-01
BR0213340A (en) 2004-10-05
ZA200403781B (en) 2004-11-29
AR037111A1 (en) 2004-10-20
RU2311172C2 (en) 2007-11-27
CN1571660A (en) 2005-01-26

Similar Documents

Publication Publication Date Title
JP4108750B2 (en) Stable composition containing N-propargyl-1-aminoindan
AU2304300A (en) Indole derivatives and their use as mcp-1 receptor antagonists
TW200503775A (en) Pharmaceutical composition and method for treating
MA29171B1 (en) DIRECT COMPRESSION FORMULATION AND METHOD THEREOF
KR20180109992A (en) A pharmaceutical composition comprising a JAK kinase inhibitor or a pharmaceutically acceptable salt thereof
WO2005070464A2 (en) A tablet formulation of clopidogrel bisulphate
TW200606164A (en) New compounds
PL234542B1 (en) Pharmaceutical compositions comprising imatinib or a pharmaceutically acceptable salt thereof and methods for their preparation
JP2018154596A (en) Azilsartan-containing solid pharmaceutical composition
KR20090097224A (en) Pharmaceutical composition comprising an indolylmaleimide derivative
CN105407925A (en) Manufacturing process for effervescent dosage forms
PE20030472A1 (en) SOLID FORMULATION TO USE AS A DRUG BASED ON A PIPERAZINUREA DERIVATIVE
MX2022013984A (en) Inhibitors of nek7 kinase.
US20040234596A1 (en) Fast disintegrating meloxicam tablet
MX2022016263A (en) Cyclobutyl-urea derivatives.
PL1789044T3 (en) Phenylaminopyridines and phenylaminopyrazines
CA2490335A1 (en) Pharmaceutical composition as solid dosage form and method for manufacturing thereof
CA2525700A1 (en) S-(-)-amlodipine nicotinate and process for the preparation thereof
NO20052491L (en) New Vitronectin Receptor Antagonist Derivatives, Methods for their Preparation, Their Use as Drugs and Pharmaceutical Compositions Containing the Same
KR20060117365A (en) Composition containing benzamidine derivative and method for stabilizing benzamidine derivative
EP1158963A1 (en) Controlled-release compositions of betahistine
BG106516A (en) Pharmaceutical agent comprising a benzamide derivative as active ingredient
KR20160003532A (en) Tenofovir disoproxil phosphate, and pharmaceutical composition comprising non-metalic salt disintegrant and non-metalic salt lubricant
JP3995414B2 (en) Stable pharmaceutical composition
NZ510115A (en) Tricyclic delta3-piperidines as alpha2-antagonists useful in the treatment of depression and Parkinson's disease

Legal Events

Date Code Title Description
FC Refusal